- Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million
- Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5,
Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness WALTHAM, Mass. , Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of
